Skip to main content
Log in

Drug Prescribing Before and During Pregnancy in South West France

A Retrolective Study

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Several drugs that are known to exhibit teratogenic or fetotoxic risks when used during pregnancy should not be prescribed to pregnant women. However, most women of childbearing age use medications, and drug use cannot always be avoided during pregnancy, especially for women with chronic diseases for whom the benefit of treatment outweighs the potential risk of the drug for the fetus. Nevertheless, it is often possible to replace a drug with another one that has been better evaluated.

Objective: The aim of the present study was to describe the prescribing of drugs to pregnant women before and during pregnancy in order to examine whether the occurrence of pregnancy modifies drug prescribing and dispensing to women. In particular, drugs that are contraindicated or must be avoided during pregnancy, such as retinoids, ACE inhibitors, angiotensin II receptor blockers, NSAIDs and valproic acid, will be analysed.

Methods: This retrolective study used data already prospectively recorded in the database of the French Health Insurance Service. It analysed pharmacy records of women who gave birth between 1 January 2007 and 31 December 2007 in Midi-Pyrenees. Pharmacy data were analysed from 9 months before pregnancy until delivery. Drugs were classified according to the Anatomical Therapeutic Chemical code.

Results: The study included 23 898 women. Approximately 77% and 96% of the women received at least one prescription before and during pregnancy, respectively. The number of women who were prescribed contraindicated drugs significantly decreased with pregnancy (p< 0.0001). Most of the drugs were stopped during the 3 months before pregnancy without alternative treatment, even for chronic diseases. However, for some women, potentially dangerous prescriptions were maintained during pregnancy, and for others these drugs were dispensed for the first time during critical periods of pregnancy.

Conclusion: Despite recommendations, some teratogenic and/or fetotoxic drugs are still prescribed and dispensed to pregnant women in France. There is a need to repeat information to sensitize health professionals and women to the harmful potential of drugs. Moreover, discontinuation of a needed treatment must be avoided. Therefore, attention must be given to ensuring that younger females and women of childbearing potential who are likely to need continued treatment in adolescence and adulthood are aware of the potential risks that some drugs may pose during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Marimbert J. Isotrétinoïne orale Renforcement du Programme de Prévention des Grossesses et rappel sur la survenue éventuelle de troubles psychiatriques, lettres aux professionnels de santé. Afssaps 2009 [online]. Available from URL: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Isotretinoine-orale-Renforcement-du-Programme-de-Prevention-des-Grossesses-et-rappel-sur-la-survenue-eventuelle-de-troubles-psychiatriques-Lettre-aux-professionnels-de-sante/(language)/fre-FR [Accessed 2011 Apr 5]

  2. Duneton P. Rappel sur la contre-indication de tous les AINS à partir du 6ème mois de grossesse, lettre aux professionnels de santé. Afssaps 2003 [online]. Available from URL: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Rappel-sur-la-contre-indication-de-tous-les-AINS-a-partir-du-debut-du-6eme-mois-de-la-grossesse/(language)/fre-FR [Accessed 2011 Apr 15]

  3. Marimbert J. Rappel sur la contre-indication des AINS à partir du début du 6ème mois de la grossesse, quelle que soit la voie d’administration, lettre aux professionnels de santé. Afssaps 2009 [online]. Available from URL: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Rappel-sur-la-contre-indication-des-AINS-a-partir-du-debut-du-6eme-mois-de-la-grossesse-quelle-que-soit-la-voie-d-administration [Accessed 2011 Apr 5]

  4. Marimbert J. Rappel sur la contre-indication des antagonistes des récepteurs de l’angiotensine II (ARA II) et des inhibiteurs de l’enzyme de conversion (IEC) au cours des 2ème et 3ème trimestres de la grossesse (princeps et génériques), lettre aux professionnels de santé. Afssaps 2008 [online]. Available from URL: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Rappel-sur-la-contre-indication-des-antagonistes-des-recepteurs-de-l-angiotensine-II-ARAII-et-des-inhibiteurs-de-l-enzyme-de-conversion-IEC-au-cours-des-2eme-et-3eme-trimestres-de-la-grossesse-princeps-et-generiques/(language)/fre-FR [Accessed 2011 Apr 15]

  5. Duneton P. Rappel sur la contre-indication des antagonistes des récepteurs de l’angiotensine II au cours des 2ème et 3ème trimestres de la grossesse. Afssaps 2003 [online]. Available from URL: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Rappel-sur-la-contre-indication-des-antagonistes-des-recepteurs-de-l-angiotensine-II-au-cours-des-2eme-et-3eme-trimestres-de-la-grossesse [Accessed 2011 Apr 5]

  6. Dictionnaire Vidal. Issy les Moulineaux: Vidal, 2009

  7. Damase-Michel C. Valproate et grossesse: effets à long terme. BIP 2005 Apr; 11:5 [online]. Available from URL: http://www.bip31.fr/bip/bip04-2005.pdf [Accessed 2011 Apr 15]

  8. Valproic acid: long-term effects on children exposed in utero. Prescrire Int 2009 Dec; 18 (104): 253–7

  9. DREES. Statistique annuelle des établissements de sante 2007 [online]. Available from URL: http://www.sae-diffusion.sante.gouv.fr/ [Accessed 2011 Apr 5]

  10. CNGOF recommandations pour la pratique Clinique Supplémentations au cours de la grossesse (1997) [online]. Available from URL: http://www.cngof.asso.fr [Accessed 2011 May 18]

  11. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008 Nov; 64(11): 1125–32

    Article  PubMed  Google Scholar 

  12. Engeland A, Bramness JG, Daltveit AK, et al. Prescription drug use among fathers and mothers before and during pregnancy: a population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 2008 May; 65(5): 653–60

    Article  PubMed  Google Scholar 

  13. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004 Nov; 60(9): 659–66

    Article  PubMed  Google Scholar 

  14. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006 May; 113(5): 559–68

    Article  PubMed  CAS  Google Scholar 

  15. Benoist BD. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. Geneva: World Health Organization, 2008

    Google Scholar 

  16. Non-anaemic pregnant women should not take iron supplements. Prescrire Int 2009 Dec 18 (104): 261–262

  17. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009 Aug; 65(8): 839–46

    Article  PubMed  CAS  Google Scholar 

  18. Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 2001; 24(6): 457–74

    Article  PubMed  CAS  Google Scholar 

  19. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008 Aug; 59(2): 295–315

    Article  PubMed  Google Scholar 

  20. Commission nationale de pharmacovigilance du 30 Septembre 2008: enquête officielle isotrétinoïne et grossesse (Roaccutane∘ et génériques), résultats préliminaires de l’enquête pharmaciens 26 novembre 2008. Afssaps, 2008 [online]. Available from URL: http://www.afssaps.fr/var/afssaps_site/storage/original/application/44c88f6d7ce134fc2c4f0a337ce33109.pdf [Accessed 2011 Apr 15]

  21. Hurault C, Lacroix I, Bourrel R, et al. Writing and dispensing of NSAID prescriptions in late pregnancy: impact of health authorities’ advice [in French]. Presse Med 2008 May; 37 (5 Pt 1): 767–74

    Article  PubMed  Google Scholar 

  22. Bouissou A, Glorieux I, Dulac Y, et al. Antenatal closure of ductus arteriosus following maternal intoxication by niflumic acid [in French]. Arch Pediatr 2006; 13(1): 48–50

    Article  PubMed  CAS  Google Scholar 

  23. Damase-Michel C, Christaud J, Berrebi A, et al. What do pregnant women know about non-steroidal anti-inflammatory drugs? Pharmacoepidemiol Drug Saf 2009 Nov; 18(11): 1034–8

    Article  PubMed  Google Scholar 

  24. Damase-Michel C, Pichereau J, Pathak A, et al. Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. Pharm Pract 2008 Jan–Mar; 6:15–9

    Google Scholar 

  25. Bowen ME, Ray WA, Arbogast PG, et al. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008 Mar; 198(3): 291.e1-5

    Article  PubMed  Google Scholar 

  26. Tomson T, Hiilesmaa V. Epilepsy in pregnancy. BMJ 2007 Oct 13; 335(7623): 769–73

    Article  PubMed  Google Scholar 

  27. Martinez-Frias ML, Rodriguez-Pinilla E. First-trimester exposure to topical tretinoin: its safety is not warranted [letter] Teratology 1999 Jul; 60(1): 5

    CAS  Google Scholar 

  28. Topical retinoids during pregnancy (continued). Prescrire Int 2005 Jun; 14(77): 100–1

    Google Scholar 

  29. Torloni M, Cordioli E, Zamith M, et al. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate. Ultrasound Obstet Gynecol 2006; 27(2): 227–9

    Article  PubMed  CAS  Google Scholar 

  30. Coulomb A, Baumelou A. Situation de l’automédication en France et perspectives d’évolution [online]. Available from URL: http://lesrapports.ladocumentationfrancaise.fr/BRP/074000030/0000.pdf [Accessed 2011 Apr 5]

  31. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology 2001 Sep; 12(5): 497–501

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christine Damase-Michel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crespin, S., Bourrel, R., Hurault-Delarue, C. et al. Drug Prescribing Before and During Pregnancy in South West France. Drug-Safety 34, 595–604 (2011). https://doi.org/10.2165/11589170-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589170-000000000-00000

Keywords

Navigation